Manitoba Renal Project is actively involved in projects and initiatives that support our goals and improve our programs and services.

Read about some of our projects here:

IKHealth

Can-SOLVE CKD Network

FINISHED Project

Electronic Kidney Health Record

eGFR Pathways for Health-Care Providers

Published research with MRP staff as contributing authors:

2017-2018

Hingwala J, Kumra R. Reducing medical administration errors in the dialysis unit. Creation and redesign of process maps, dialysis flow and treatment sheets, and standardized tools for dialysis staff.

Hingwala J. A3 implementation for staff initiatives. Educating and training nephrology staff on A3 worksheet.

Basaraba G, Lyndsay A, Bueti G, Hingwala J. Dialysis medication requisitions. Creation and implementation of specialized medication requisitions for chronic dialysis patients when they are admitted to hospital.

Hingwala J. Improve clinic patient flow and efficiency. Create process mapping and value stream mapping to reduce redundancies, improve workflow, better train new clinic staff, and reduce omission errors.

Hingwala J, Komenda P, Tangri N. Quality indicators for the Manitoba Renal Program (MRP). Translating the MRP strategic plan goals to quality indicator measures that are accurate and actionable.

Improving responsiveness across the continuum of kidney health care in rural and remote Manitoba First Nation communities (IKHealth) co-Principal applicants : Dr. Josee Lavoie, Caroline Chartrand, Lorraine McLeod, James Zacharias. CIHR – 5 year funding starting April 1, 2018, $1,575,000.00

Hingwala J, Tangri N, Komenda P, Armstrong S, Paretz D, Cuvelier, S, Peritoneal dialysis catheters for the treatment of refractory ascites management:  A randomized un-blinded pilot study.

Publications

St. Peter WL, Wazny LD, Weinhandl ED. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies. Am J Kidney Dis 2018;71(2):246-53.

St. Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ. A review of phosphate binders in chronic kidney disease: Incremental progress of just higher costs? Drugs 2017, 77(11):1155-86.

Wazny L, Moist L.Ch. 100 Chronic Kidney Disease.  In: Gray, J, ed. Compendium of Therapeutic Choices 2017 ed. Ottawa, ON: Canadian Pharmacists Association, 2017.

Hudson JQ, Wazny LD.  Ch. 44 Chronic Kidney Disease.  In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach 10^th ed. New York, NY.: McGraw Hill Companies, Inc.; 2017.

St. Peter W., Wazny L, Weinhandl E. FR-PO882 Phosphate binder use and cost trends in US dialysis patients. J Am Soc Nephrol Oct 2017;28(abstract ed):631. American Society of Nephrology (ASN) Annual Meeting, New Orleans, LA (Nov 2-5, 2017).

Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, Rigatto C, Tangri N. Safety of Intravenous Iron in  Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2018 Mar 7;13(3):457-467. doi: 10.2215/CJN.0539051. Epub 2018 Feb 20. PubMed PMID: 29463597; PubMed Central PMCID: PMC5967668.

Smekal MD, Tam-Tham H, Finlay J, Donald M, Benterud E, Thomas C, Quinn RR, Tam K, Manns BJ, Tonelli M, Bello A, Tangri N, Hemmelgarn BR. Perceived Benefits  and Challenges of a Risk-Based Approach to Multidisciplinary Chronic Kidney Disease Care: A Qualitative Descriptive Study. Can J Kidney Health Dis. 2018 Mar 23;5:2054358118763809. doi:  0.1177/2054358118763809. eCollection 2018. PubMed PMID: 29636981; PubMed Central PMCID: PMC5888822.

Collister D, Tangri N. Conventional Risk Factors Associated With Meaningful Outcomes in Advanced CKD. Kidney Int Rep. 2018 Mar 15;3(3):513-515. doi: 10.1016/j.ekir.2018.02.013. eCollection 2018 May. PubMed PMID: 29854958; PubMed Central PMCID: PMC5976847

Arora RC, Tangri N. All that glitters may not be gold: Changes in serum creatinine may not be the criterion standard for acute kidney injury. J Thorac Cardiovasc Surg. 2018 Jun;155(6):2439-2440. doi: 10.1016/j.jtcvs.2018.01.047. Epub 2018 Feb 8. PubMed PMID: 29530573.

Bohm CJ, Storsley LJ, Hiebert BM, Nelko S, Tangri N, Cheskin LJ, McAdams-DeMarco MA, Rigatto C. Impact of Exercise Counseling on Physical Function in Chronic Kidney Disease: An Observational Study. Can J Kidney Health Dis. 2018

Feb 19;5:2054358117753615. doi: 10.1177/2054358117753615. eCollection 2018. PubMed PMID: 29487746; PubMed Central PMCID: PMC5821295.

Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other

Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. PubMed PMID: 29540325.

Harasemiw O, Milks S, Oakley L, Lavallee B, Chartrand C, McLeod L, Di Nella M, Rigatto C, Tangri N, Ferguson T, Komenda P. Remote Dwelling Location Is a Risk Factor for CKD Among Indigenous Canadians. Kidney Int Rep. 2018 Feb 10;3(4):825-832. doi: 10.1016/j.ekir.2018.02.002. eCollection 2018 Jul. PubMed PMID: 29989009; PubMed Central PMCID: PMC6035135.

Levin A, Adams E, Barrett BJ, Beanlands H, Burns KD, Chiu HH, Chong K, Dart A, Ferera J, Fernandez N, Fowler E, Garg AX, Gilbert R, Harris H, Harvey R, Hemmelgarn B, James M, Johnson J, Kappel J, Komenda P, McCormick M, McIntyre C,

Mahmud F, Pei Y, Pollock G, Reich H, Rosenblum ND, Scholey J, Sochett E, Tang M,  Tangri N, Tonelli M, Turner C, Walsh M, Woods C, Manns B. Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD):

Form and Function. Can J Kidney Health Dis. 2018 Jan 17;5:2054358117749530. doi: 10.1177/2054358117749530. eCollection 2018. PubMed PMID: 29372064; PubMed Central PMCID: PMC5774731.

Wu J, Dong M, Santos S, Rigatto C, Liu Y, Lin F. Lab-on-a-Chip Platforms for  Detection of Cardiovascular Disease and Cancer Biomarkers. Sensors (Basel). 2017  Dec 17;17(12). pii: E2934. doi: 10.3390/s17122934. Review. PubMed PMID: 29258216;

PubMed Central PMCID: PMC5751502.

Liu P, Quinn RR, Oliver MJ, Ronksley PE, Hemmelgarn BR, Quan H, Hiremath S, Bello AK, Blake PG, Garg AX, Johnson J, Verrelli M, Zacharias JM, Abd ElHafeez S, Tonelli M1, Ravani P. (2018). Association between Duration of Predialysis Care and Mortality after Dialysis Start.Clin J Am Soc Nephrol.

Zelenitsky SA, Howarth J, Lagacé-Wiens P, Sathianathan C, Ariano R, Davis C, Verrelli M. (2017). Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. Peritoneal Dialysis International 2017 Mar-Apr. 37(2): 170-176.

• Validation of the Kidney Failure Risk Equation in Manitoba
• Anemia management in chronic kidney disease and dialysis: a narrative review.
• Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
• A Dynamic Predictive Model for Progression of CKD
• Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 To 2014
• ANCA Associated Vasculitis Secondary to Levamisole-Adultered Cocaine with Associated Membranous Nephropathy: A Case Series
• Care of Manitobans Living with Chronic Kidney Disease – Manitoba Centre for Health Policy
• Dignity and Distress towards the End of Life across Four Non-Cancer Populations
• An ethanol/sodium citrate locking solution compared to heparin to prevent hemodialysis catheter-related infections: a randomized pilot study
• PLOS ONE: An Economic Assessment Model of Rural and Remote Satellite Hemodialysis Units
• Differentiating between apparent and actual rates of H2O2 metabolism by isolated rat muscle mitochondria to test a simple model of mitochondria as regulators of H2O2 concentration
•  The Prevalence of CKD in Rural Canadian Indigenous Peoples: Results From the First Nations Community Based Screening to Improve Kidney Health and Prevent Dialysis (FINISHED) Screen, Triage, and Treat Program
•  Pasteurella species peritoneal dialysis-associated peritonitis: Household pets as a risk factor
•  The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis
• IMPACT OF MODALITY CHOICE ON RATES OF HOSPITALIZATION IN PATIENTS ELIGIBLE FOR BOTH PERITONEAL DIALYSIS AND HEMODIALYSIS
•  Maintenance of Mycobacterium tuberculosis-specific T cell responses in End Stage Renal Disease (ESRD) and implications for diagnostic efficacy
• Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use
• CABG or PCI: which is better for revascularization of coronary artery disease in chronic kidney disease?
• The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review
• Effect of Time on Dialysis and Renal Transplantation on Endothelial Function: A Longitudinal Analysis

• Impact of modality choice on rates of hospitalization in patients eligible for both peritoneal dialysis and hemodialysis.
• Intensive Hemodialysis and Health-Related Quality of Life
• Intensive Hemodialysis and Potential Risks With Increasing Treatment
• Intensive Hemodialysis and Treatment Complications and Tolerability
• Mass screening for chronic kidney disease in rural and remote Canadian first nations people: methodology and demographic characteristics
• Effect of a preventive foot care program on lower extremity complications in diabetic patients with end-stage renal disease
• Dignity and Distress towards the End of Life across Four Non-Cancer Populations
• Evaluating the implementation strategy for estimated glomerular filtration rate reporting in Manitoba: the effect on referral numbers, wait times, and appropriateness of consults